Bumetanide vs. Furosemide in Cirrhosis

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Stacy Johnson
Study ID
NCT06941415
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cirrhosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bumetanide — DRUG
    Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
  • Furosemide — DRUG
    Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders

Study Details

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.

Key Dates

Start date
May 18, 2026
Status verified
Apr 2026
Primary completion
Mar 1, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bumetanide
  • Experimental: Furosemide

Primary Outcome Measure

Percent change in weight [ Time Frame: 7 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Utah HospitalSalt Lake CityUtah84132
Andrea T White, PhD
[email protected]
801-581-7818
Stacy A Johnson, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Salt Lake City, UT

By research site
University of Utah Hospital· Salt Lake City, UT

Related Studies